1stOncology™: Cancer Intelligence Service – Page 4543 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Leap Therapeutics to Participate at Upcoming Investor Conferences

On September 5, 2023 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences (Press release, Leap Therapeutics, SEP 5, 2023, View Source [SID1234634923]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Leap Presentation Details:

H.C. Wainwright 25th Annual Global Investment Conference
Date: Monday, September 11th, 2023
Time: 7:00 a.m. Eastern Time

Baird Global Healthcare Conference
Date: Wednesday, September 13th, 2023
Time: 3:10 p.m. Eastern Time

A replay of the pre-recorded H.C. Wainwright presentation and a live webcast of the Baird fireside chat may be accessed on the Investors page of the company’s website at View Source, where a replay of the events will also be available for a limited time.

XtalPi and Parthenon Enter Into AI-Powered Antibody Discovery Partnership

On September 5, 2023 XtalPi, a global leader in AI-powered drug discovery, and Parthenon Therapeutics, a clinical-stage biotechnology company dedicated to reprogramming the tumor microenvironment, reported their collaboration today to discover novel therapeutic antibodies for the treatment of solid tumors (Press release, Parthenon Therapeutics, SEP 5, 2023, View Source [SID1234634921]).

Under this agreement, XtalPi will grant Parthenon Therapeutics access to its proprietary XupremAb antibody discovery platform, which is a collection of solutions that leverage AI and wet lab techniques to deliver therapeutic antibody candidates with superior efficacy and developability profiles. Parthenon Therapeutics and XtalPi will utilize multiple approaches in the XupremAb platform for deeper interrogation of the immune repertoire and generating a large, consolidated dataset, which will be further mined by XtalPi’s proprietary algorithms for exceptional candidates.

"We are excited to work with Parthenon Therapeutics on this pioneering project. Their strong innovation in tumor barrier disruption and deep understanding of the target, coupled with our broadly validated AI-powered antibody discovery platform, forms a solid foundation for the development of next-generation cancer therapeutics," said Yi Li, VP of Antibody Discovery, XtalPi.

"We are very pleased to collaborate with XtalPi to leverage their cutting-edge proprietary platform to deeply mine the immune repertoire to discover novel state-of-the-art antibody therapeutics. Combined with Parthenon’s vast expertise in biotherapeutic drug discovery and unique insights into the tumor microenvironment and the mechanisms underlying immune exclusion, we look forward to developing transformative therapies for cancer patients," said Tom McCaughtry, VP – Head of Research, Parthenon Therapeutics.

Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate

On September 5, 2023 Beactica Therapeutics AB, the Swedish precision oncology company, reported the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers (Press release, Beactica, SEP 5, 2023, View Source [SID1234634920]).

BEA-17 is a first-in-class small molecule which has shown promising potentiation of immune-modulating treatments in preclinical models of several cancer forms. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM), the most aggressive form of brain tumour. With the selection of this first preclinical candidate, IND-enabling toxicology studies will be initiated in preparation for clinical trials.

"We are thrilled to announce the selection of BEA-17 as a preclinical candidate. Reaching this remarkable milestone is a major achievement, as the vast majority of programmes fail at the preclinical stage." said Dr Per Källblad, CEO of Beactica Therapeutics. "The selection of this molecule reflects our aim to test this new approach in humans as quickly as possible."

About BEA-17

BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of lysine demethylase 1 (LSD1) and its co-factor CoREST. In syngeneic animal models of cancer, the compound has shown promising potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in colon cancer (CT26) and standard of care (temozolomide and radiation) in glioblastoma (GL261). Pharmacokinetic studies of BEA-17 show good blood-brain-barrier penetration and oral availability. BEA-17 is investigational and not approved anywhere globally. Its efficacy and safety in humans have not been established. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM).

IDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events

On September 5, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in upcoming investor relations events (Press release, Ideaya Biosciences, SEP 5, 2023, View Source [SID1234634919]).

Citi 18th Annual BioPharma Conference
Wednesday, September 6th, 2023 at 1:00 PM ET

Targeted Oncology Panel participation by Paul Stone, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst.
Morgan Stanley 21st Annual Global Healthcare Conference
Monday, September 11th, 2023 at 10:40 AM ET

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Ryuk Byun, MD, Executive Director.
A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.

I-Mab Announces Upcoming Participation at September Conferences

On September 5, 2023 I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, reported its participation in the following conferences in September 2023 (Press release, I-Mab Biopharma, SEP 5, 2023, View Source [SID1234634918]). Details of the conferences and management presentation are as follows:

H.C. Wainwright 25th Annual Global Investment Conference (Hybrid)

Presentation: Monday, September 11th at 11:30 a.m. E.S.T

Presenter: Mr. Raj Kannan, CEO

One-on-one and small group meetings: Sept 11-13, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; Dr. Andrew Zhu, President and Head of R&D; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your H.C. Wainwright representative.

2023 Cantor Global Healthcare Conference (In Person)

Presentation: Thursday, September 28th at 2:25 p.m. E.S.T.

Presenter: Mr. Raj Kannan, CEO; and Dr. John Hayslip, CMO

One-on-one and small group meetings: Sept 26-28, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Cantor representative.